Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Mantle-Cell

Explore clinical trials studying Lymphoma, Mantle-Cell. Study availability and eligibility vary by location and protocol.

889 public trials 111 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Mantle-Cell trial results

Not Yet Recruiting

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

NCT04913103

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • University Hospital Brno Brno, Czechia
  • University Hospital Hradec Králové Hradec Králové, Czechia
  • University Hospital Olomouc Olomouc, Czechia
  • University Hospital Ostrava Ostrava, Czechia
View Trial Details
Completed

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

NCT05024045

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +29 more
Locations
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • City of Hope National Medical Center Duarte, California, United States
  • University of California San Francisco, Medical Center at Paranassus San Francisco, California, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
View all 23 locations
View Trial Details
Completed

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

NCT03323151

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • Georgia Cancer Center at Augusta University Augusta, Georgia, United States
  • Carle Cancer Center Urbana, Illinois, United States
  • University of Kansas Overland Park, Kansas, United States
View all 14 locations
View Trial Details
Completed

Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT01838434

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • University of Chicago Chicago, Illinois, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • Ohio State University Medical Center Columbus, Ohio, United States
View Trial Details
Completed

Evaluating Different Doses of Orelabrutinib in MCL

NCT05978739

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui, China
  • The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Chongqing Cancer Hospital Chongqing, Chongqing Municipality, China
View all 20 locations
View Trial Details
Completed

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

NCT02242097

Conditions
Contiguous Stage II Mantle Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Northwestern University- Lake Forest Hospital Lake Forest, Illinois, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Cleveland Clinic Cleveland, Ohio, United States
View Trial Details

Related conditions